Abstract 4214
Background
High-grade osteosarcoma (HGOS) is the most common primary malignant bone tumor. In metastatic patients, survival rates are poor and remained virtually unchanged over the past 30 years. Furthermore, recent randomized trials failed to improve the efficacy of current chemotherapy. Here we tested the anti-neoplastic activity of a novel peptide-conjugated alkylator melflufen in preclinical osteosarcoma setting. Due to its high lipophilicity melflufen rapidly enters tumor cells where it is immediately cleaved by peptidases leading to entrapment and enrichment of alkylating payload. Overexpression of peptidases is often seen in tumor cells and can thus lead to increased melfufen sensitivity. In osteosarcoma, over-expression of aminopeptidase N (ANPEP/CD13) has been associated with poor survival and metastasis suggesting that melflufen may represent a valid new therapeutic option.
Methods
Gene expression of ANPEP/CD13 in patient samples from GEO datasets was analyzed using standard tools. Anti-neoplastic activity of melflufen and was evaluated in a panel of 11 osteosarcoma cell lines including early passage patient-derived primary lines. In vitro anti-neoplastic activity was examined using survival and apoptosis assays. In vivo activity of melflufen was tested in a chicken embryo xenograft model.
Results
Melflufen has demonstrated superior anti-neoplastic activity in comparison to other alkylating agents including melphalan, cyclophosphamide, ifosfamide, busulfan, and bendamustine. Melflufen was active in all osteosarcoma cell lines including the cells resistant to methotrexate, etoposide, and talazoparib. Anti-neoplastic activity of melflufen could be hindered by ANPEP inhibitor bestatin. Furthermore, in vivo administration of melflufen reduced tumor growth and metastasis of highly aggressive 143B osteosarcoma cells in a xenograft model.
Conclusions
Melflufen has demonstrated promising results in preclinical osteosarcoma model showing anti-neoplastic activity superior to other alkylating agents and PARP inhibitor talazoparib. Melflufen’s favorable toxicity profile suggests that it might represent a novel valid therapeutic approach for osteosarcoma patients with poor response to chemotherapy and metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Oncopeptides AB.
Disclosure
A. Slipicevic: Full / Part-time employment: Oncopeptides AB. K. Byrgazov: Research grant / Funding (self): Oncopeptides AB. F. Lehmann: Full / Part-time employment: Oncopeptides AB; Leadership role: EpiEndo Pharmaceuticals. T. Lion: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Incyte. All other authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract